Abstract: The present invention provides a pharmaceutical composition comprising an iron chelating agent exhibiting antitumor activity, antimicrobial activity, and/or antivirus activity and having reduced side effects. Specifically, the present invention provides a pharmaceutical composition for use in treatment of cancer or infectious disease, comprising an iron chelating agent that selectively binds to biologically unstable iron, rather than to transferrin-bound iron.

Abstract: A chelate compound wherein a chelate-forming moiety is attached to a base compound having an amino group and at least a part of the amino group is in the form of a halide salt. A specific example of the halide salt is hydrochloride. As the base compound, a chitosan having a glucosamine skeleton is preferred. Also, chitosan beads are usable. The chelate compound is produced by reacting the base compound having an amino group with an aldehyde group of an aromatic cyclic compound, aromatic cyclic compound having at least a functional group capable of forming a chelate and the aldehyde group, to form a Schiff base, reducing the Schiff base with a reducing agent and then treating with a hydrohalogenic acid (hydrochloric acid).

Abstract: Disclosed is a water-insoluble polymeric iron chelating agent having a polymer backbone and an aromatic ring attached to the polymer backbone through an —NH—CH2— bond, wherein the aromatic ring has one or two first functional groups in the form of hydroxyl group and one or two second functional groups located at the ortho position with respect to the first functional group; and wherein the second functional group is —OH, —COOH, or a group represented by formula (I) wherein A represents —CH3, —CH2—CH3, —CH2—C6H5, —CH2—C5H4N or —CH2—COOH and B represents —CH2—COOH. The water-insoluble polymeric iron chelating agent of the present invention offers the advantages of being capable of selectively chelating iron ions, particularly biologically unstable iron, and being insoluble in water, and moreover not being incorporated in metabolic processes in vivo.

Abstract: A chelate compound wherein a chelate-forming moiety is attached to a base compound having an amino group and at least a part of the amino group is in the form of a halide salt. A specific example of the halide salt is hydrochloride. As the base compound, a chitosan having a glucosamine skeleton is preferred. Also, chitosan beads are usable. The chelate compound is produced by reacting the base compound having an amino group with an aldehyde group of an aromatic cyclic compound, aromatic cyclic compound having at least a functional group capable of forming a chelate and the aldehyde group, to form a Schiff base, reducing the Schiff base with a reducing agent and then treating with a hydrohalogenic acid (hydrochloric acid).

Abstract: Provided are an adsorptive carbon which can effectively adsorb vivotoxins such as advanced glycation end products (AGEs), and an adsorbent containing the adsorptive carbon as an active ingredient. The adsorptive carbon according to the present invention has a total pore volume of 0.10 to 1.0 mL/g, an average pore diameter of 1.0 to 2.0 nm, and an absorbance of an infrared absorption band at 1650-1800 cm?1 of no less than 0.005.

Abstract: Disclosed is a water-insoluble polymeric iron chelating agent having a polymer backbone and an aromatic ring attached to the polymer backbone through an —NH—CH2— bond, wherein the aromatic ring has one or two first functional groups in the form of hydroxyl group and one or two second functional groups located at the ortho position with respect to the first functional group; and wherein the second functional group is —OH, —COOH, or a group represented by formula (I) wherein A represents —CH3, —CH2—CH3, —CH2—C6H5, —CH2—C5H4N or —CH2—COOH and B represents —CH2—COOH. The water-insoluble polymeric iron chelating agent of the present invention offers the advantages of being capable of selectively chelating iron ions, particularly biologically unstable iron, and being insoluble in water, and moreover not being incorporated in metabolic processes in vivo.

Abstract: Provided are an adsorptive carbon which can effectively adsorb vivotoxins such as advanced glycation end products (AGEs), and an adsorbent containing the adsorptive carbon as an active ingredient. The adsorptive carbon according to the present invention has a total pore volume of 0.10 to 1.0 mL/g, an average pore diameter of 1.0 to 2.0 nm, and an absorbance of an infrared absorption band at 1650-1800 cm?1 of no less than 0.005.